Vaccinex, Inc. announced the appointment of Robert Scala as Chief Commercial Officer, effective September 1, 2020. Robert will build and lead all commercial functions at Vaccinex and provide strategic and functional oversight of commercial operations for the Company starting with pepinemab, potentially the first disease modifying treatment for Huntington’s disease. He will report to Maurice Zauderer, Ph.D., President and CEO, and serve as a member of the Company’s Executive Team. Prior to joining the Company, Mr. Scala served as the Vice President, Business Planning & Commercial Operations for DBV Technologies, a biotech start-up focused on immunotherapies for food allergies, from October 2017 to July 2020.